Schundler Russell sold $1.1M of LQDA

Schundler Russell (General Counsel) sold 14,738 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $1.05M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schundler Russell
Published Jul 15, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to change the fundamental outlook.

03

What to watch

The article does not disclose whether additional insiders sold, whether there were concurrent buybacks, or any new company-specific catalysts; those would matter more for price.

Relevance 5/10Novelty 4/10Timing: Filed 2026-07-14 after trades on 2026-07-13

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by its General Counsel.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp Form 4 shows General Counsel Schundler Russell sold 14,738 shares in open-market trades totaling about $1.05M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless accompanied by other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 transaction with explicit 10b5-1 pre-arrangement, and the article provides no new operational, financial, or regulatory developments.

Market effects

No clear sector read-through from a single officer sale disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales under a 10b5-1 plan can be purely mechanical for liquidity or tax planning, so the signal may be overstated.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Schundler Russell

    General Counsel who sold 14,738 shares in two trades.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, suggesting scheduled/structured selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.